The silent killer after transplant: What you need to know about graft-versus-host disease

The silent killer after transplant: What you need to know about graft-versus-host disease

Understanding Graft-Versus-Host Disease (GVHD) Graft-versus-host disease (GVHD) is a severe complication that can occur after an allogeneic stem cell or bone marrow transplant. This condition arises when the immune cells from the donor (the graft) recognize the recipient’s body (the host) as foreign and initiate an attack on various tissues. The development of graft-versus-host disease […]

Niktimvo FDA approval brings new hope for chronic graft-versus-host disease patients

Niktimvo FDA approval brings new hope for chronic graft-versus-host disease patients

The U.S. Food and Drug Administration (FDA) has approved Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, for treating chronic graft-versus-host disease (GVHD) in patients who have not responded to at least two previous systemic therapies. This approval marks a significant advancement in the treatment options available for both adult and pediatric patients weighing at least 40 kg […]